Answers are grounded in this paper and cite their sources.
Findings position iHF-MSCs for consistent production of therapeutic secretome, suggesting new immunomodulatory approaches.
These results position iHF-MSCs as a robust and scalable platform for consistent production of therapeutic secretome, paving the way for innovative, cell-free immunomodulatory and regenerative therapies.
No takes yet. Share an insight, caveat, or question.
Rossello-Gelabert et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: